A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

(2018) E E Vokes et al.   ANNALS OF ONCOLOGY

Abstract PD6-01: Prevalence of PDL1 and tumor infiltrating lymphocytes (TILs) in primary and metastatic TNBC

(2018) Y Li et al.   CANCER RESEARCH

Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients

(2018) J. Garde-Noguera et al.   Clinical & Translational Oncology

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial

(2018) Motohiro Tamiya et al.   PLoS One

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

(2018) Andrea Botticelli et al.   Journal of Translational Medicine

Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data

(2017) Elizabeth Dudnik et al.   LUNG CANCER

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

(2017) Paul C. Tumeh et al.   Cancer Immunology Research

Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer

(2016) Takehito Shukuya et al.   Journal of Thoracic Oncology

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE